IL-1β inhibition with canakinumab has recently been shown to reduce cardiovascular events in patients with coronary arterial disease and has also been shown to decrease immune activation in treated HIV patients, but there are concerns about its safety, particularly infectious complications [99, 100]. This evidence concerns the gene IL1B and coronary artery disorder.